Psychedelic Mushrooms: The Use of Psilocybin in the Treatment of Mental Disorders
Correa Rms
Annals of Bioethics & Clinical Applications 2024 DOI: 10.23880/abca-16000266 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Psilocybin |
| Keywords | Hallucinogen Psychotherapist |
| Citations | 1 |
| Key findings | Psilocybin shows promise as a safe and valid therapeutic alternative for psychiatric disorders in controlled settings, but requires further study. |
Abstract
Psychedelics are a class of hallucinogenic drugs. They have been explored particularly for treatment-resistant psychiatric illnesses. In recent years, advances in psychopharmacology have benefited thousands of patients with some type of mental disorder. Preliminary evidence has shown that psilocybin has shown promise in the treatment of psychiatric disorders, with the support of qualified doctors. Recent clinical studies have reported marked improvements in mental health in psilocybinassisted psychotherapy. In many studies, the safety and efficacy of psilocybin have been the primary objectives to show that it is a safe and valid therapeutic alternative to other forms of psychiatric medications. Currently, some studies prove that psilocybin is safe in a controlled environment. However, the use of psilocybin needs to be further studied to determine the efficacy and safety of potential applications in medicine.
Comparable studies
Other narrative reviews on psilocybin, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. General population | 2019 | Integrative review | |
| The pharmacology of psilocybin | 2002 | Review | |
| Serotonin research: contributions to understanding psychoses | 2008 | Review | |
| Psychedelics, Meditation, and Self-Consciousness | 2018 | Review | |
| The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act | 2018 | Review |
Citations in the library
Cites 21
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer Archives of General Psychiatry September 7, 2010
and 16 more in the library